Updated phase 2 data showed a 60% ORR and 86% CNS ORR with frontline silevertinib in non-classical EGFR-mutant NSCLC; FDA discussion supported a phase 3 trial in 2027.
|Videos|October 11, 2016
EGFR Testing for Metastatic Non-Small Cell Lung Cancer with Jonathan W. Riess, MD, MS: Case 1
EGFR Testing for Metastatic Non-Small Cell Lung Cancer with Jonathan W. Riess, MD, MS
Advertisement
Riess case 1:
A 44-year-old female with relapsed stage IV adenocarcinoma.
- This is a 44-year-old female diagnosed with stage IV adenocarcinoma
- Tissue-based mutation testing showed an EGFR mutation with exon 19 deletion
- She was subsequently treated with afatinib
- After 11 months she became mildly symptomatic with small, nonspecific pulmonary nodules
- Follow up CT scan showed growth of the primary lesion
- The patient reported worsening of her cough
- Cell-free DNA testing was ordered and was negative for both the EGFR driver mutation and for T790M
- Subsequent tissue biopsy showed the presence of T790M
- The patient was switched to osimertinib and continues to respond well to therapy with minimal toxicity
Advertisement
Related to this article
FDA issues a not approvable letter for Novocure’s Optune Mya in NSCLC brain metastases, citing uncertain clinical benefit. No safety concerns were raised.
Imneskibart showed promising outcomes and tolerability in patients who had previously received immune checkpoint inhibition for either melanoma or lung adenocarcinoma.
In KEYNOTE-867, adding pembrolizumab to radiotherapy did not extend event-free survival in inoperable early-stage NSCLC and raised toxicity; the phase 3 trial was stopped for futility in 2024.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves OncoMate MSI Dx For Pembrolizumab in MSI-H Tumors
2
Novocure’s Optune Mya Gets FDA Not Approvable Letter
3
Anbal-Cel Demonstrates Clinical Activity in Relapsed LBCL
4
In Phase 3, Ponatinib/Blinatumomab Improves EFS in Ph+ ALL
5